'Steady decline' in C-peptide starts six months before T1D diagnosis

The findings suggest an early window of opportunity for disease-modifying therapy, researchers say

A longitudinal study tracking people as they develop type 1 diabetes shows that C-peptide levels maintain a steady decline starting six months before clinical diagnosis.

Vial of blood to be tested for C-peptide

The results suggest that interventions aimed at reducing damage to beta-cells might need to be carried out earlier than previously thought, the US authors say.

Data for 80 people enrolled in the TrialNet Pathway to Prevention study were used. All had relatives with type 1 diabetes and were